The purpose of this study is to find out the side effects and safety of a combination of the
CXCR2 antagonist, AZD5069 in combination with the androgen receptor antagonist, enzalutamide
in patients with metastatic castration resistant prostate cancer and to determine the most
appropriate dose of this combination. During the phase I study, patients will receive AZD5069
orally twice daily (BD) in combination with enzalutamide at 160mg orally once daily
continuously. The starting dose of AZD5069 will be 40mg BD (dose level 1): other doses to be
evaluated will include 80mg BD (dose level 2), 120mg BD (dose level 3), 160mg BD (dose level
4) and 320mg BD (dose level 5) in order to determine the MTD and RP2D to take forward to a
Phase II reversal of resistance cohort. Intermediate dose levels such as 240mg BD may also be
evaluated. During dose levels 1 to 4, patients will start with AZD5069 monotherapy for two
weeks before commencing the combination. At all other dose levels, the two agents will be
started concurrently. In addition, if agreed by the SRC, intermediate dose levels such as 240
mg taken BD will be explored. The Phase II part of the study will evaluate the optimized
dose/schedule identified in Phase I of the study in patients with metastatic castration
resistant prostate cancer.
In the Phase I part of the study, the AZD5069 is started first and will be taken twice daily
as an oral tablet at Cycle 1, Day -14 for 14 days. Two weeks later on Cycle 1 Day 1, patients
will start taking 160mg enzalutamide once a day in addition to the AZD5069. The starting dose
of AZD5069 will be 40mg taken orally twice daily with single dose escalations to 80mg, 120mg
and 160mg taken orally twice daily to determine the MTD to take forward to a Phase II
reversal of resistance cohort.
The Phase II reversal of enzalutamide resistance study will explore whether the addition of
AZD5069 to enzalutamide reverses resistance to enzalutamide alone. In the phase II reversal
of enzalutamide resistance study patients will start taking the AZD5069 at the dose
established in the Phase I safety run in part of the study in combination with 160mg of
enzalutamide once a day and at the same time from Cycle 1 Day 1 onwards.
If the MTD of AZD5069 is greater than 160 mg BD, two different dose levels may be taken
forward to the phase II study to determine efficacy. Only patients who have experienced
disease progression after at least 12 weeks of treatment with enzalutamide, apalutamide or
darolutamide will be eligible for this trial. Those patients who progressed on enzalutamide,
apalutamide or darolutamide (at least 12 weeks of therapy) greater than 6 months prior to
starting the IMP will enter the Phase II enzalutamide resistance run in cohort to confirm
resistance to enzalutamide; once progression on enzalutamide is confirmed they will enter the
Phase II reversal of enzalutamide resistance cohort.
Up to approximately 86 patients will be enrolled into this phase I/II trial, with up to 36
patients in the phase I safety run in cohort depending on number of patients required to
determine the RP2D and up to 50 patients in the phase II study. We predict around 50% of
these patients will enter the phase II enzalutamide resistance run in cohort first. The
anticipated accrual rate for this trial is 3-6 patients per month across 4 centres.
Inclusion Criteria:
1. Written informed consent and be capable of cooperating with treatment.
2. Age ≥ 18 years
3. Histologically confirmed adenocarcinoma of the prostate and with tumour tissue
accessible for research analysis for this trial. Patients who have no histological
diagnosis must be willing to undergo a biopsy to prove prostate adenocarcinoma.
4. Metastatic castration resistant prostate cancer.
5. Documented prostate cancer progression as assessed by the investigator with RECIST
(v1.1) and PCWG2 criteria (section 3.6) with at least one of the following criteria:
a. Progression of soft tissue/visceral disease by RECIST (v1.1) and/or, b. Progression
of bone disease by PCWG2 bone scan criteria and/or, c. Progression of PSA by PCWG2 PSA
criteria and/or, d. Clinical progression with worsening pain and need for palliative
radiotherapy for bone metastases.
6. PSA ≥ 10ng/ml.
7. Received prior castration by orchiectomy and/or ongoing luteinizing hormone releasing
hormone agonist treatment.
8. Ongoing androgen deprivation with serum testosterone < 50 ng/dL (<2.0 nM).
9. Willing to have pre- and post-treatment biopsies to obtain proof of mechanism from
translational studies. Archival tissue must be available for research analysis
10. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.
11. Documented willingness to use an effective means of contraception while participating
in the study and for 6 months post last treatment dose as defined in section 9.6.
12. Able to swallow the study drug.
13. All efforts should be made to discontinue steroid usage but up-to 5mg BD prednisolone
(or equivalent) will be allowed.
14. Haematological and biochemical indices within the ranges shown below. These
measurements must be performed within one week (Day -7 to Day 1) before the patient
goes in the trial.
Laboratory Test Value required Haemoglobin (Hb) ≥ 9.0 g/dL Absolute neutrophil count ≥
1.5 x 109/L Platelet count ≥ 100 x 109/L WBC ≥ 3.0 x 109/L Calculated creatinine
clearance ≥ 50 mL/min (uncorrected value) Serum bilirubin ≤ 1.5 x upper limit of
normal (ULN) unless documented Gilbert's disease. Alanine aminotransferase (ALT) and
aspartate aminotransferase (AST)
≤ 2.5 x (ULN) unless raised due to known metastatic liver disease in which case ≤ 5 x
ULN is permissible
15. Phase I safety run in cohort ONLY Patients that have progressed after either
enzalutamide, apalutamide, darolutamide or abiraterone treatment (having received a
minimum of 12 weeks of enzalutamide, apalutamide, darolutamide or abiraterone
treatment).
16. Patients with histologically confirmed adenocarcinoma of the prostate that have
progressed after either enzalutamide, apalutamide or darolutamide (having received a
minimum of 12 weeks of enzalutamide, apalutamide or darolutamide) more than 6 months
prior to entry (day of starting IMP). Prior treatment with abiraterone is not an
exclusion criteria.
17. Patients with histologically confirmed adenocarcinoma of the prostate that have
progressed after either enzalutamide. apalutamide or darolutamide (having received a
minimum of 12 weeks enzalutamide, apalutamide or darolutamide ) within 6 months prior
to entry (day of starting IMP). Prior treatment with abiraterone is not an exclusion
criteria.
Exclusion Criteria:
- 1. Surgery, chemotherapy or other anti-cancer therapy within 4 weeks prior to trial
entry/randomization into the study (with the exception of enzalutamide, apalutamide or
darolutamide). Any other therapy for prostate cancer, other than gonadotropin
releasing hormone analogue therapy, such as progesterone, medroxyprogesterone,
progestins or 5-alpha reductase inhibitors, must be discontinued at least 2 weeks
before the first dose of the study drug.
2. Participation in another interventional clinical trial of an IMP within 4 weeks
prior to trial entry. Participation in trials of licenced medications is allowed
provided the medication is not a prohibited concomitant medication.
3. Prior limited field radiotherapy within 2 weeks and wide field radiotherapy within
4 weeks prior to trial entry.
4. Clinical and/or biochemical evidence of hyperaldosteronism or hypopituitarism.
5. History of seizures or other predisposing factors including, but not limited to,
underlying brain injury, stroke, primary brain tumours, brain metastases and
leptomeningeal disease, or alcoholism.
6. Use of potent inhibitors/inducers of CYP3A4, CYP2C9 and CYP2C19 should be avoided
during the trial and 4 weeks prior to trial entry.
Co-administration of drugs that are known potent or moderate CYP3A4 inhibitors, potent or
moderate CYP3A4 inducers (with the exception of enzalutamide), P-gp substrates with narrow
therapeutic index, sensitive CYP2B6 substrates, warfarin or any other coumarin derivative,
BCRP-substrates that reduce blood neutrophils, Seville orange or grapefruit products.
Use of herbal medications during the trial and 4 weeks afterwards. 7. Malabsorbtion
syndrome or other condition that would interfere with enteral absorption.
8. Any of the following cardiac criteria:
- • QT interval > 470 msec.
- Clinically important abnormalities including rhythm, conduction or ECG changes (left
bundle branch block, third degree heart block).
- Factors predisposing to QT prolongation including heart failure, hypokalemia,
congenital long QT syndrome, family history of prolonged QT syndrome, unexplained
sudden death (under 40) and concomitant medications known to prolong QT interval.
- Coronary artery bypass, angioplasty, vascular stent, myocardial infarction, angina or
congestive heart failure (NYHA ≥ grade 2) in the last 6 months (see appendix 4 for
NYHA scale).
- Uncontrolled hypotension (systolic blood pressure < 90mmHg and or diastolic blood
pressure < 50 mmHg).
- Uncontrolled hypertension on optimal medical management 9. Clinically significant
history of liver disease (Chlid-Pugh B or C, viral or other hepatitis, current alcohol
abuse or cirrhosis).
10. Any other finding giving reasonable suspicion of a disease or condition that
contraindicates the use of an investigational drug or that may affect interpretation
of the results or renders the patients at high risk from treatment complications e.g
patients with a hypersensitivity to the active substance or any of the excipients.
11. Malignancy other than prostate cancer within 5 years of trial entry with the
exception of adequately treated basal cell carcinoma.
12. Unresolved significant toxicity from prior therapy (except alopecia and grade 1
peripheral neuropathy).
13. Inability to comply with study and follow-up procedures. 14. Patients with
predominantly small cell or neuroendocrine differentiated prostate cancer are not
eligible.
15. Immunocompromised patients. 16. Active or uncontrolled autoimmune disease
requiring corticosteroid therapy.
17. History of thromboembolic disease within 12 months of commencement of trial.
18. At high-risk because of non-malignant systemic disease including active infection
and any serious concurrent illness.
19. Any known intolerance to enzalutamide, AZD5069 or to any constituents
20. Symptoms of COVID-19 and/or documented COVID-19 infection
